Clinical Trial Update: An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme-naive Cross-Reacting Immunologic Material (CRIM[-]) Patients With Infantile-Onset Pompe Disease [Phase 4]

View source ↗

Summary

Phase 4 exploratory trial evaluating the safety and efficacy of prophylactic immunomodulatory treatment in Myozyme-naive CRIM-negative infants with Pompe diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glycogen Storage Disease Type Ii
• Pompe Disease

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Pompe Disease, Glycogen Storage Disease Type II | Phase 4 | Status: COMPLETED | Results posted: 2014-05-13